Sign in
Active, not recruitingNo phase

Neurotechnology Following Traumatic Brain Injury

Key facts

Who runs it
Brain State Technologies, LLC
Where
Bethesda and Fort Bragg, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
People taking part
80 people enrolled
Started
28 Aug 2018
Ended
1 Jul 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • HIRREM-SOP or Cereset
  • Cereset 2x
Record updated
14 August 2023

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 43 criteriaShow less

Who can take part

  • 1 Must have symptoms related to concussion or TBI, not healthy controls Age 18 years or older
  • 2 Active duty or retired military service member, or dependent beneficiary
  • 3 History of mild TBI, confirmed by administration of the Ohio State University TBI
  • Identification Method Interview
  • 4 At least three months, and no more than ten years, since their most recent TBI
  • 5 Persistent symptoms temporally related, or otherwise attributable to, the TBI, such as
  • headache or chronic pain, sensory disturbance including auditory, visual or other sensory
  • symptoms, balance difficulties, or dizziness. After obtaining informed consent, sufficient
  • severity of symptoms for entry into the study will be confirmed by administration of the
  • Neurobehavioral Symptom Inventory (NSI), with a score of 23 or higher required for
  • inclusion
  • 6 Willingness to be randomly assigned to one of the two treatment groups and to provide
  • data for all study measures
  • 7 Willingness to abstain from alcohol or recreational drug use throughout the intervention
  • period and up to 3 weeks after completion of the final office-based intervention session
  • This abstention period is intended to support the stabilization of new brain activity
  • patterns that may result from the intervention
  • 8 For individuals using any of the following medication classes (either regularly scheduled
  • or PRN), a willingness both to discontinue or hold those medications at least five (5) halflives
  • prior to the initiation of study procedures, and throughout the period of participation
  • in the study, as well as to sign a release enabling contact between study staff and their
  • prescribing provider, to ensure that the prescriber deems that holding said medication
  • during the study period is permissible and reasonable: benzodiazepines, opioids, antipsychotics,
  • mood-stabilizers, anti-convulsants, non-benzodiazepine sleep aids (including
  • but not limited zolpidem, eszoplicone, zaleplon, trazadone, and diphenhydramine), other
  • prescribed sedative-hypnotics, or medical marijuana or cannabinoid medication
  • 9 Willingness to abstain from initiation of PRN/as needed usage of the above listed
  • medications throughout the period of study participation. This criterion only applies to
  • new PRN prescription or usage. There is no requirement to abstain from a new, regularly scheduled prescription for one of the above medications during the course of the study, if the participant's provider
  • deems such usage to be indicated. The potential impact of the initiation of any such
  • medications during the study will be assessed by conducting sensitivity analyses after the
  • completion of the study
  • 10 Willingness to alert study investigators of any changes in their medication usage
  • throughout the course of their study participation

Who cannot take part

  • 2 A history of moderate or severe TBI
  • 3 The diagnosis of a psychotic disorder (including schizophrenia and schizoaffective
  • disorder), severe depression (PHQ-9 score > 20), bipolar disorder, or active suicidal or
  • 6 Meeting criteria for a current alcohol or substance use disorder
  • 1 Unable or unwilling to demonstrate an understanding of the nature and intent of the
  • study, and/or to complete informed consent procedures
  • homicidal ideation
  • 4 Physically unable to come to the study visits, or to sit in a chair for up to two hours
  • 5 Inability to hear and repeat a phrase spoken at normal conversational volume

Where in United States

  • Uniformed Services UniversityBethesda, United States
  • Womack Army Medical CenterFort Bragg, United States

About the trial

What the trial wants to find out

This two-part study seeks to improve symptoms such as pain and sleep problems after concussion, or mild traumatic brain injury (mTBI).

Read full original descriptionShow less

Study I evaluates symptoms of mTBI through a series of 10 office sessions in which musical tones are echoed, or mirrored back in real time, to reflect one's own brain activity. Those who take part in the study will be randomly assigned to receive either tones that are based on their brain activity/brainwaves, or random tones.

Study II evaluates symptoms of mTBI through either 10 office sessions of the same acoustic stimulation linked to brain activity/brainwaves as Study I compared to 5 office sessions of acoustic stimulation plus intermittent very low level electrical stimulation of the scalp linked to brain activity.

The 2 groups in the trial

  • HIRREM-SOP or CeresetExisting treatment, for comparison

    HIRREM-SOP is a novel, noninvasive, closed-loop, BrainEcho, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time. This group will have 10 sessions.

  • Cereset 2xExisting treatment, for comparison

    Participants randomized to the Cereset 2x group will be seated in a comfortable zero-gravity chair identical to those in the HIRREM-SOP arm. They will listen to a pattern of musical notes linked to their brain activity patterns, but also receive intermittent very low level electrical stimulation of the scalp linked to brain activity. This group will only have 5 sessions,

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Controlled Trials of Closed-loop Allostatic Neurotechnology to Improve Sensory Function and Pain Management After Traumatic Brain Injury
Publications
Record updated
14 August 2023